Research in Obstetrics and Gynecology

Research in Obstetrics and Gynecology is a peer-reviewed international journal that publishes articles on all aspects of basic and clinical research in the fields of obstetrics and gynecology and related subjects, with emphasis on matters of worldwide interest. The journal publishes invited and submitted reviews and original articles about clinical topics and basic research; case reports; and preliminary communications from all sub-specialties in gynecology and obstetrics.

Douglas Taylor

Editorial Board Member of Research in Obstetrics and Gynecology

Professor, University of Louisville School of Medicine, USA

Research Areas

Exosomal Regulation of Immune Responses

Education

1978-1982Ph.DDepartment of Biochemistry, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC
1976-1978M.S.Department of Biochemistry, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC
1973-1976B.S.Chemistry & Biology, University of Richmond, Richmond, VA

Experience

2008-presentVice Chair for Research, Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, KY
2006-presentProfessor, Department of Microbiology & Immunology, University of Louisville School of Medicine, Louisville, KY
2004-presentProfessor, Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, KY
2000-presentMember, Tumor Immunology Group, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY
1995-2003Associate Professor, Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, KY
1992-1994Assistant Professor, Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, KY
1988-1992Assistant Professor, Department of Surgery, Adjunct Assistant Professor, Department of Biochemistry, Temple University School of Medicine Philadelphia, PA
1988-1992Director of Research, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA
1988-1992Associate Member, Division of Medical Sciences, Fox Chase Cancer Center, Philadelphia, PA
1987-1988Assistant Professor, Department of Microbiology and Immunology, Boston University School of Medicine, Boston, MA
1985-1987Instructor, Department of Microbiology and Immunology, Boston University School of Medicine, Boston, MA

Academic Achievement

Award for Research Excellence in Medical Science, Sigma Xi, 1979
National Individual Research Service Award, National Institutes of Health-National Cancer Institute (Tumor Immunology), 1983-1985
Whitaker Health Science Foundation Research Award, with Dr. S. Tonegawa, 1987-1989
Society for Gynecologic Investigation President’s Award, with Dr. A. Eblen-45th Annual Meeting of the Society for Gynecologic Investigations, 1998
Pfizer Award for Outstanding Research in Obstetrics & Gynecology, 1998
Jewish Hospital Foundation Award for Research with Major Clinical Application, 1998
American College of Obstetrics & Gynecology, Searle-Donald F. Richardson Research Award, with Dr. Christopher Watkins, 1999
American College of Obstetrics & Gynecology, Searle-Donald F. Richardson Research Award, with Dr. Karen Lyons, 2001
University of Louisville School of Medicine, Letitia Kimsey Endowed Lectureship, 2006, 2007, 2008, 2009
Faculty Excellence Award for Exclusive License Agreement to Immunotheragnostics, 2008
Faculty Excellence Award for South African Patent on "Modification of exosomal components for use as a cancer vaccine", October 2010

Membership

1986-present, American Association for Cancer Research
1999–present, American Association of Immunologists
2000–present, American Society for Reproductive Immunology
2002–present, Society for the Study of Reproduction
2004–present, Society for Women’s Health Research

Publications: Journals

[1]  †Taylor D.D. and Doellgast, G.J. Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Analytical Biochemistry, 98:53-59, 1979.
[2]  Taylor, D.D., Homesley, H.D., and Doellgast, G.J. Binding of specific peroxidase-labeled antibody to placental-type alkaline phosphatase on tumor-derived membrane fragments. Cancer Research, 40:4064-4069, 1980.
[3]  †Taylor, D.D., Homesley, H.D., and Doellgast, G.J. Membrane-associated immunoglobulins in cyst and ascites fluids of ovarian cancer patients. American Journal of Reproductive Immunology, 3:7-11, 1983.
[4]  Taylor, D.D., Chou, I.N., and Black, P.H.. Isolation of plasma membrane fragments from cultured murine melanoma cells. Biochemical and Biophysical Research Communication, 113:470-476, 1983.
[5]  Taylor, D.D., Homesley, H.D., and Doellgast, G.J. Identification of components responsible for the autologous humoral responses of ovarian cancer patients. American Journal of Reproductive Immunology, 6:179-184, 1984.
[6]  Taylor, D.D. and Black, P.H. Inhibition of macrophage Ia antigen expression by shed plasma membrane vesicles from metastatic murine melanoma lines. Journal of the National Cancer Institute, 74:859-867, 1985.
[7]  Poutsiaka, D.D., Schroder, E.W., Taylor, D.D., Levy, E.M., and Black, P.H. Shed membrane vesicles from murine melanoma cells selectively inhibit the expression of Ia antigens by macrophages. Journal of Immunology, 134:138-144, 1985.
[8]  Poutsiaka, D.D., Taylor, D.D., Levy, E.M., and Black, P.H. Inhibition of recombinant interferon-gamma induced Ia antigen expression. Journal of Immunology, 134:145-150, 1985.
[9]  Poutsiaka, D.D., Yogeeswaren, G., Taylor, D.D., and Black, P.H. Turnover and fate of I-Ak antigen on the murine macrophage cell surface. Biochemical and Biophysical Research Communication, 131:216-221, 1985.
[10]  **Hollander, D.M., Devereux, D.F., Gerçel-Taylor, C., and Taylor, D.D. Demonstration of lipolytic activity from cultured human melanoma cells. Journal of Surgical Research, 40: 445-449, 1986.
[11]  Devereux, D.F., Hollander, D.M., Gerçel-Taylor, C., and Taylor, D.D. Effect of retinoic acid lipolytic activity from cultured human melanoma cells. Surgery, 102:277-282, 1987.
[12]  Taylor, D.D., Gerçel-Taylor, C., Jiang, C.G., and Black, P.H. Characterization of plasma membrane shedding from murine melanoma cells. International Journal of Cancer, 41:629-635, 1988.
[13]  Taylor, D.D., Gerçel-Taylor, C., and Weese, J.L. Expression and shedding of mdr-1 antigen by variants of the murine B16 melanoma. Surgical Forum, 40:406-408, 1989.
[14]  Taylor, D.D., Gerçel-Taylor, C., Jiang, C.G., Chou, I.N., and Black, P.H. Alterations of cellular characteristics of a human ovarian teratocarcinoma cell line after in vitro treatment with retinoids. Differentiation, 43:123-130, 1990.
[15]  **Jiang, C.G., Taylor, D.D., and Black, P.H. Effect of retinoic acid on tumor-mediated immunologic alterations in mice bearing metastatic B16 melanoma variants. International Journal of Cancer, 46:1054-1058, 1990.
[16]  Gatenby, R.A. and Taylor, D.D. Suppression of wound healing in tumor-bearing animals as a model for tumor-host interactions: Mechanisms of suppression. Cancer Research, 50:7997-8001, 1990.
[17]  Keller, S.M., Taylor, D.D., and Weese, J.L. In vitro killing of human malignant mesothelioma by photodynamic therapy. Journal of Surgical Research, 48:337-340, 1991.
[18]  **Pelton, J.J., Taylor, D.D., Gerçel-Taylor, C., Carp, N.Z., and Weese, J.L. Lymphokine activated killer (LAK) cell suppressor factor in malignant effusions. Archives of Surgery, 126:476-480, 1991.
[19]  Eisenberg, B.L., Taylor, D.D., and Weese, J.L. Activation of pulmonary alveolar macrophages by aerolized immunomodulators. Journal of Immunotherapy, 10:51-56, 1991.
[20]  Taylor, D.D., Gerçel-Taylor, C., Jenis, L.G., and Devereux, D.F. Identification of a human tumor-derived lipolysis-promoting factor. Cancer Research, 52:829-834, 1992.
[21]  Gatenby, R.A., Taylor, D.D., and Ellison, D.J. Identification of a novel cell population in nonhealing wounds in tumors. Journal of Surgical Research, 53:188-194, 1992.
[22]  Eisenberg, B.L., Lanciano, R.M., Nussbaum, M.L., Klein-Szanto, A., and Taylor, D.D. Intraoperative liver radiation after partial hepatectomy in a rat model. Journal of Surgical Research, 53:287-292, 1992.
[23]  **Yeung, R., Vollmer, C., Taylor, D., Palazzo, J., and Weese, J. Intratumoral recombinant interleukin-2 based immunotherapy in B16 melanoma. Journal of Surgical Research, 53:203-210, 1992.
[24]  Taylor, D.D., Gerçel-Taylor, C., Fowler, W.C., and Weese, J.L. Enhancement of antitumor effects of combined chemoimmunotherapy. Journal of Immunotherapy, 13:91-97, 1993.
[25]  **Gwin, J.L., Gerçel-Taylor, C., Taylor, D.D., and Eisenberg, B.L. Role of LFA-3, ICAM-1 and MHC Class I antigens on the sensitivity of tumor cells to LAK cells. Journal of Surgical Research, 60:129-136, 1996.
[26]  Gerçel-Taylor, C., Hoffman, J.P., Taylor, D.D., Owens, K.J., and Eisenberg, B.L. Interleukin-2 activation of cytotoxic cells in post-mastectomy seroma. Journal of Surgical Research, 61:89-96, 1996.
[27]  Gerçel-Taylor, C., Doering, D.L., Kraemer, F.B., and Taylor, D.D. Aberrations in normal systemic lipid metabolism of gynecologic cancer patients. Gynecologic Oncology, 60:35-41, 1996.
[28]  Gerçel-Taylor, C. and Taylor, D.D. Effect of patient-derived lipids on in vitro expression of oncogenes by ovarian tumor cells. Gynecologic and Obstetric Investigations, 42:42-48, 1996.
[29]  Taylor, D.D., Gerçel-Taylor, C., and Gall, S.A. Expression and shedding of CD44 isoforms by gynecologic cancer patients. Journal of the Society for Gynecologic Investigations, 3:289-294, 1996.
[30]  Taylor, D.D., Gerçel-Taylor, C., and Weese, J.L. Modulation of colon tumor oncogene expression by cancer patient-derived lipids. Journal of Surgical Oncology, 63:46-51, 1996.
[31]  **Gibb, R.K., Gerçel-Taylor, C., Taylor, D.D., O'Connor, D.M., and Doering, D.L. Apoptosis as a measure of chemosensitivity to cisplatin and Taxol therapy in ovarian cancer cell lines. Gynecologic Oncology, 65: 13-22, 1997.
[32]  *Chinni, S.R., Gerçel-Taylor, C., Falchetto, R.A., Shabanowitz, J., Hunt, D.F., and Taylor, D.D. Cathepsin D and glucose-regulated protein 78 recognized by the humoral response of ovarian cancer patients. Clinical Cancer Research, 3: 1557-1564, 1997.
[33]  Yashar, C.M., Taylor, D.D., and Gerçel-Taylor, C. Changes in the sensitivity of tumor cells to LAK mediated lysis during progression of ovarian cancer. American Journal of Reproductive Immunology, 38:431-437, 1997.
[34]  Weeks, J., Reynolds, L., Taylor, D., Lewis, J., Wan, T., Mailhes, J., and Gall, S.A. Elevated interleukin-6 levels in umbilical cord blood are associated with neonatal morbidity. Obstetrics and Gynecology, 90:815-818, 1997.
[35]  *Shields, L.B.E., Gerçel-Taylor, C., Yashar, C.M., Katsanis, W.A., and Taylor, D.D. Pregnancy-induced immunization against ovarian cancer. Journal of the Society for Gynecologic Investigations, 4:298-304, 1997.
[36]  *Chinni, S.R., Gerçel-Taylor, C., Conner, G.E., and Taylor, D.D. Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients. Cancer Immunology and Immunotherapy, 46:48-54, 1998.
[37]  **Katsanis, W.A., Shields, L.B.E., Gerçel-Taylor, C., Spinnato, J.A., and Taylor, D.D. Immune recognition of endometrial tumor antigens induced by multiparity. Gynecologic Oncology, 70: 33-39, 1998.
[38]  Yashar, C.M., Gerçel-Taylor, C., Weeks, J.W., and Taylor, D.D. Identification of unique form of p53 in human cord blood associated with the development of material autoantibodies. American Journal of Reproductive Immunology, 39:368-375, 1998.
[39]  Schneider, C.C., Gibb, R.K., Taylor, D.D., Wan, T., and Gerçel-Taylor, C. Growth regulation of endometrial cancer cell lines by RU486. Journal of the Society for Gynecologic Investigation, 5: 334-338, 1998.
[40]  **Jones, J.N., Gerçel-Taylor, C., and Taylor, D.D. Altered cord serum lipid levels associated with small-for-gestational age infants. Obstetrics and Gynecology, 93: 527-531, 1999.
[41]  **Bazzett, L.B., Gerçel-Taylor, C., Watkins, C.S., and Taylor, D.D. Modulation of proliferation and chemosensitivity by procathepsin D in ovarian cancer. Gynecologic Oncology, 74: 181-187, 1999.
[42]  Makhija, S., Taylor, D.D., Gibb, R.K., and Gerçel-Taylor, C. Regulation of chemotherapy induced apoptosis in ovarian cancer cell spheroids. International Journal of Oncology, 14: 515-521, 1999.
[43]  Lei, Z.M., Taylor, D.D., Gerçel-Taylor, C., and Rao, C.V. Human chorionic gonadotropin promotes tumorigenesis of choriocarcinoma JAR cells. Trophoblast Research, 13:147-159, 1999.
[44]  **Eblen, A.C., Gerçel-Taylor, C., Shields, L.B.E., Sanfillipo, J.S., Nakajima, S.T., and Taylor, D.D. Alterations in humoral immune responses associated with recurrent pregnancy loss. Fertility and Sterility, 73: 305-313, 2000.
[45]  Gerçel-Taylor, C., Bazzett, L.B., and Taylor, D.D. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with gynecologic malignancies. Gynecologic Oncology, 81:71-76, 2001.
[46]  Bosscher, J.R., Gerçel-Taylor, C., Watkins, C.S., and Taylor, D.D. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients. Gynecologic Oncology, 81: 138-143, 2001.
[47]  Taylor, D.D., Bender, D.P., Gerçel-Taylor, C., Stanson, J., and Whiteside, T.L. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. British Journal of Cancer, 84:1624-1629, 2001.
[48]  **Whitecar, P.W., Boggess, K.A., McMahon, M.J., Thorp, J.M., Jr., Taylor, D.D. Altered expression of TcR/CD3-zeta induced by sera from women developing preeclampsia. American Journal of Obstetrics and Gynecology, 185:812-818, 2001.
[49]  Manahan, K.J., Taylor, D.D., and Gercel-Taylor, C. Clonal heterogeneity of p53 mutations in ovarian cancer. International Journal of Oncology, 19:387-394, 2001.
[50]  Gercel-Taylor, C., Ackermann, M., and Taylor, D.D. Evaluation of cell proliferation and cell death assays in determination of ovarian cancer cell sensitivity to cisplatin and paclitaxel. Anticancer Research, 21:2761-2768, 2001.
[51]  Taylor, D.D., Sullivan, S.A., Eblen, A.C., and Gerçel-Taylor, C. Modulation of T-cell CD3-zeta chain expression during normal pregnancy. Journal of Reproductive Immunology, 54:15-31, 2002.
[52]  Taylor, D.D., Lyons, K.S., and Gercel-Taylor, C. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecologic Oncology, 84:443-448, 2002.
[53]  **Eblen, A.C., Nakajima, S., Gerçel-Taylor, C., and Taylor, D.D. Early modulation of T-Cell Zeta Chain Expression in IVF patients. American Journal of Reproductive Immunology, 47:167-173, 2002.
[54]  Gercel-Taylor, C., O'Connor, S.M., Lam, G.K., and Taylor, D.D. Shed membrane fragment modulation of CD3-zeta during pregnancy: Link with induction of apoptosis. Journal of Reproductive Immunology, 56: 29-44, 2002.
[55]  Dehaven, K., Taylor, D.D., and Gercel-Taylor, C. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. International Journal of Gynecologic Oncology, 12:715-719, 2002.
[56]  Singh, N.P., Yolcu, E.S., Taylor, D.D., Gercel-Taylor, C., Metzinger, D.S., Dreisbach, S.K., and Shirwan H. A novel approach to cancer immunotherapy: Tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Research, 63:4067-4073, 2003.
[57]  **Bazzett, L.B., Magnus, M., Taylor, D.D., Gercel-Taylor, C. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecologic Oncology, 90:435-442, 2003.
[58]  †Taylor, D.D. Gercel-Taylor. C., Lyons, K.S., Stanson, J., and Whiteside, T.L. Suppression of TcR/CD3-zeta by shed membrane vesicles from ovarian tumors. Clinical Cancer Research, 9: 5113-5119, 2003 (Featured article).
[59]  **Lam, G.K., Whitecar, P.W., Orton, S., Boggess, K.A., and Taylor, D.D. Differential expression of TcR-CD3 zeta as evidence for altered immunoregulation in preeclamptic versus normotensive women. American Journal of Obstetrics and Gynecology, 189:843-847, 2003.
[60]  Gercel-Taylor, C., Feitelson, A.K., Taylor, D.D. Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. AntiCancer Research, 24: 795-800, 2004.
[61]  Gercel-Taylor, C., Edwards, R.P., Case, C.R., Taylor, D.D. Immunologic evaluation of response to IL-2 treatment in ovarian cancer patients. Gynecologic Oncology, 94: 54-60, 2004.
[62]  †Taylor, D.D., Gercel-Taylor, C. Alterations in T-Cell Signal Transduction Molecules Associated with Recurrent Spontaneous Pregnancy Loss. Journal of Reproductive Immunology, 63: 137-154, 2004 (Featured article).
[63]  †Taylor, D.D., Gercel-Taylor, C. Tumor-derived exosomes as mediates of T-cell signaling defects. British Journal of Cancer, 92: 305-311, 2005 (Featured article).
[64]  Kim, J.W., Wieckowski, E., Taylor, D.D., Reichert, T.E., Watkins, S., Whiteside, T.L. FasL+ membraneous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clinical Cancer Research, 11: 1010-1020, 2005 (Featured article).
[65]  Saxena, A., Yashar, C., Taylor, D.D., Gercel-Taylor, C. Cellular response to chemotherapy and radiation in cervical cancer. American Journal of Obstetrics and Gynecology, 192:1399-1403, 2005.
[66]  Yashar, C.M., Spanos, W.J., Taylor, D.D., Gercel-Taylor, C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecologic Oncology, 99: 199-205, 2005.
[67]  Gercel-Taylor, C., Scobee, J.J., Taylor, D.D. Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. AntiCancer Research, 25: 2113-2117, 2005.
[68]  Taylor, D.D., Akyol, S., Gercel-Taylor, C. Pregnancy-associated exosomes and their modulation of T-cell signaling. Journal of Immunology, 176: 1534-1542, 2006.
[69]  Erkanli, A., Taylor, D.D., Dean, D., Eksir, F., Egger, D., Geyer, J., Nelson, B.H., Stone, B., Fritsche, H.A., Roden, R.B. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Research, 66: 1792-1798, 2006.
[70]  Metzinger, D.S., Taylor, D.D., Gercel-Taylor, C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Letters, 236: 302-308, 2006.
[71]  Taylor, D.D., Bohler, H.C., Gercel-Taylor, C. Pregnancy-linked suppression of TcR signaling pathways by a circulating factor absent in recurrent spontaneous pregnancy loss. Molecular Immunology, 43: 1872-1880, 2006.
[72]  Singh, N.P., Miller, R.W., Yolcu, E.S., Kilinc, O., Oechsli, M., Huseby, R., Taylor, D.D., Perry, M.T., LaRocca, R.V., Shirwan, H. Primary Tumor Cells from Cancer Patients "Decorated" With a Novel Form of CD80 Protein Serve as Effective Antigen-Presenting Cells for the Induction of Autologous T-Cell Immune Responses Ex Vivo. Human Gene Therapy, 17: 334-346, 2006.
[73]  Akyol, S., Gercel-Taylor, C., Reynolds, L.C., Taylor, D.D. HSP-10 in ovarian cancer: Expression and suppression of T-cell signaling. Gynecologic Oncology, 101:581-486, 2006.
[74]  **Sabapatha, A., Gercel-Taylor, C., Taylor, D.D. Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences. American Journal of Reproductive Immunology, 56:345-55, 2006.
[75]  Randall-Whitis, L., Taylor, D.D., Gercel-Taylor, C. cDNA microarray analysis of gene expression in ovarian cancer cells after treatment with carboplatin and paclitaxel. Cancer Genomics & Proteomics, 3: 289-294, 2006.
[76]  Abdallah, M.A., Kang, S., Taylor, D.D., Nakajima, S.T., Gercel-Taylor, C. The effects of components of hormone replacement therapy on matrix metalloproteinases in breast cancer cells: An in vitro study. Fertility and Sterility, 87: 978-981, 2007
[77]  **Shondel SM, Helm CW, Gercel-Taylor C, Taylor DD. Differential expression of T-cell CD3-zeta chains in patients with cervical dysplasia before and after treatment. International Journal of Gynecological Cancer. 17:1278-82, 2007.
[78]  Bohler HC. Gercel-Taylor C. Lessey BA. Taylor DD. Endometriosis markers: immunologic alterations as diagnostic indicators for endometriosis. Reproductive Sciences. 14:595-604, 200, 2007.
[79]  Abdallah MA. Abdullah HI. Kang S. Taylor DD. Nakajima ST. Gercel-Taylor C. Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study. Fertility & Sterility. 87:978-81, 2007.
[80]  †Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology, 110:13-21, 2008.
[81]  **Parry, J.P., Taylor, D.D., Nakajima, S.T., Gercel-Taylor, C. Genistein Reverses Diminished T cell Signal Transduction, Induced by Postmenopausal Estrogen Levels. American Journal of Reproductive Immunology, 61: 26-33. 2009.
[82]  **Rabinowits, G., Gercel-Taylor C., Day, J.M., Taylor, D.D., Kloecker, G.H. Exosomal microRNA: A diagnostic marker for lung cancer. Clinical Lung Cancer, 10: 42-46, 2009.
[83]  **Ku L.T., Gercel-Taylor, C., Nakajima, S.T., Taylor, D.D. Alterations of T cell activation signaling and cytokine production by postmenopausal estrogen levels. Immunity and Ageing, 6:1-7, 2009.
[84]  Parker, L.P., Taylor, D.D., Gercel-Taylor, C. Modulation of miRNAs associated with ovarian cancer cells by genistein. European Journal of Gynaecological Oncology, 30:616-621, 2009.
[85]  Parker LP, Taylor DD, Kesterson S, Gercel-Taylor C. Gene expression profiling in response to estradiol and genistein in ovarian cancer cells. Cancer Genomics and Proteomics, 6: 189-194, 2009.
[86]  Taylor, D.D., Gercel-Taylor, C., Parker, L.P. Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer. Gynecologic Oncology, 115:112-120, 2009.
[87]  Swoboda, R.K., Somasundaram, R., Caputo, L., Berencsi, K., von Franzke, P., Taylor, D.D., Marincola, F.M., Meropol, N.J., Sigurdson, E., Miller, E., Herlyn, D. Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. International Journal of Cancer, 127: 1124-30, 2010.
[88]  Taylor DD, Atay S, Metzinger DS, Gercel-Taylor C. Characterization of humoral responses of ovarian cancer patients: Antibody subclasses and antigenic components. Gynecologic Oncology, 116:213-221, 2010.
[89]  *Atay S, Gercel-Taylor C, Suttles J, Mor G, Taylor DD. Trophoblast derived exosomes mediate monocyte recruitment and differentiation. American Journal of Reproductive Immunology, 65: 65-77, 2011.
[90]  Xiang X, Liu Y, Zhuang X, Zhang S, Michalek S, Taylor DD, Grizzle W, Zhang HG TLR2 mediated expansion of MDSCs is dependent on the source of tumor exosomes. American Journal of Pathology, 177: 1606-1610, 2010.
[91]  Atay S., Gercel-Taylor C., Kesimer M., Taylor, D.D. Morphologic and proteomic characterization of exosomes released by cultured extravillous trophoblast cells. Experimental Cell Research, 317: 1192-1202, 2011.
[92]  Atay S., Gercel-Taylor C., Taylor, D.D. Human trophoblast-derived exosomal fibronectin induces pro-inflammatory IL-1β production by macrophages. American Journal of Reproductive Immunology, in press.

Publications: Books/Book Chapters

[1]  Taylor, D.D. and Black, P.H. Neoplastic and developmental importance of plasma membrane vesicles. American Zoologist, 26:411-415, 1987.
[2]  Taylor, D.D. and Gercel-Taylor, C. Autologous tumor-reactive immunoglobulins in ovarian cancer patients. Oncology Reports, 5:1519-1524, 1998.
[3]  Taylor, D.D. and Gercel-Taylor, C. Exosomes/Microvesicles as mediators of cancer progression. http//educationbook.aacrjournals.org, 2011.
[4]  Taylor, D.D., Levy, E.M., and Black, P.H. Shed membrane vesicles: A mechanism for tumor induced immunosuppression. In: Immunity to Cancer (M.S. Mitchell and A.E. Reif, eds.) pp. 369-373, 1985.
[5]  Taylor, D.D. and Black, P.H. Shedding of plasma membrane fragments: Neoplastic and develpomental importance. In: Developmental Biology (M. Steinberg, ed.) vol. 3, pp. 33-57, 1986.
[6]  Gerçel-Taylor, C. and Taylor, D.D. Effect of in vivo mobilized lipids on the expression of oncogene products by human colon tumor cells. In: Diet and Cancer: Molecular mechanisms of interactions (ed. under auspices of the American Institute for Cancer Research) pp. 203, 1995.
[7]  Taylor, D.D., Zacharias, W., and Gercel-Taylor, C. Exosome isolation for proteomic analyses and RNA profiling. In: Methods in Molecular Biology (RJ Simpson, ed), 728: 235-246, 2011.
[8]  Taylor, D.D., Gerçel-Taylor, C.: Exosomes/Microvesicles: Mediators of cancer-associated immunosuppressive microenvironments. Seminars in Immunopathology, (J. Schifferli, ed), Springer (in press).
[9]  Roberson, C., Atay, S., Gercel-Taylor, C., Taylor, D.D.: Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomarkers: Biomarkers in Ovarian cancer, (A. Lokshin and W. Tainsky eds.). in press